{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:27:08Z","timestamp":1792708028339,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13555-025-01444-9","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T08:00:46Z","timestamp":1748073646000},"page":"1755-1770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Narrative Review of Pemphigoid Diseases: Bridging Associations, Comorbidities, and Management"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1257-0022","authenticated-orcid":false,"given":"Emma L.","family":"Myers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7692-6446","authenticated-orcid":false,"given":"Donna A.","family":"Culton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"issue":"9863","key":"1444_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(12)61140-4.","journal-title":"Lancet"},{"key":"1444_CR2","unstructured":"Baigrie D, Nookala V. Bullous pemphigoid. 2023 Mar 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls; 2025 Jan."},{"issue":"4","key":"1444_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103036","volume":"21","author":"G Du","year":"2022","unstructured":"Du G, Patzelt S, van Beek N, Schmidt E. Mucous membrane pemphigoid. Autoimmun Rev. 2022;21(4):103036. https:\/\/doi.org\/10.1016\/j.autrev.2022.103036.","journal-title":"Autoimmun Rev"},{"key":"1444_CR4","unstructured":"Bernett CN, Fong M, Yadlapati S, Rosario-Collazo JA. Linear IGA dermatosis. 2023 Aug 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls; 2025 Jan."},{"issue":"8","key":"1444_CR5","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.autrev.2019.06.007","volume":"18","author":"K Kridin","year":"2019","unstructured":"Kridin K, Kneiber D, Kowalski EH, Valdebran M, Amber KT. Epidermolysis bullosa acquisita: a comprehensive review. Autoimmun Rev. 2019;18(8):786\u201395. https:\/\/doi.org\/10.1016\/j.autrev.2019.06.007.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"1444_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fmed.2018.00220","volume":"20","author":"K Kridin","year":"2018","unstructured":"Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne). 2018;20(5):220. https:\/\/doi.org\/10.3389\/fmed.2018.00220.","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"1444_CR7","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1001\/jamadermatol.2024.3425","volume":"160","author":"P Chou","year":"2024","unstructured":"Chou P, Yu C, Wen C, Tu Y, Chi C. Bullous pemphigoid severity and levels of antibodies to BP180 and BP230: a systematic review and meta-analysis. JAMA Dermatol. 2024;160(11):1192\u2013200. https:\/\/doi.org\/10.1001\/jamadermatol.2024.3425.","journal-title":"JAMA Dermatol"},{"issue":"54","key":"1444_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jdcr.2024.09.019","volume":"11","author":"EL Myers","year":"2024","unstructured":"Myers EL, Googe PB, Culton DA. Treatment of immune checkpoint inhibitor-induced bullous pemphigoid with methotrexate. JAAD Case Rep. 2024;11(54):31\u20136. https:\/\/doi.org\/10.1016\/j.jdcr.2024.09.019.","journal-title":"JAAD Case Rep"},{"issue":"14","key":"1444_CR9","doi-asserted-by":"publisher","first-page":"1196999","DOI":"10.3389\/fimmu.2023.1196999","volume":"29","author":"J Huttelmaier","year":"2023","unstructured":"Huttelmaier J, Benoit S, Goebeler M. Comorbidity in bullous pemphigoid: up-date and clinical implications. Front Immunol. 2023;29(14):1196999. https:\/\/doi.org\/10.3389\/fimmu.2023.1196999.","journal-title":"Front Immunol"},{"issue":"15","key":"1444_CR10","doi-asserted-by":"publisher","first-page":"adv00224","DOI":"10.2340\/00015555-3457","volume":"100","author":"MJ Verheyden","year":"2020","unstructured":"Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug-induced pemphigoid. Acta Derm Venereol. 2020;100(15):adv00224. https:\/\/doi.org\/10.2340\/00015555-3457.","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"1444_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","volume":"158","author":"MS Asdourian","year":"2022","unstructured":"Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST. Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review. JAMA Dermatol. 2022;158(8):933\u201341. https:\/\/doi.org\/10.1001\/jamadermatol.2022.1624.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1444_CR12","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","volume":"83","author":"AN Geisler","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255\u201368. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.132.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1444_CR13","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3389\/fimmu.2019.02466","volume":"22","author":"K Kridin","year":"2019","unstructured":"Kridin K, Ahmed AR. Anti-p200 pemphigoid: a systematic review. Front Immunol. 2019;22(10):2466. https:\/\/doi.org\/10.3389\/fimmu.2019.02466.","journal-title":"Front Immunol"},{"issue":"7","key":"1444_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041769","volume":"7","author":"K Vafia","year":"2012","unstructured":"Vafia K, Groth S, Beckmann T, et al. Pathogenicity of autoantibodies in anti-p200 pemphigoid. PLoS ONE. 2012;7(7):e41769. https:\/\/doi.org\/10.1371\/journal.pone.0041769.","journal-title":"PLoS ONE"},{"issue":"2","key":"1444_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jdermsci.2013.01.001","volume":"70","author":"H Koga","year":"2013","unstructured":"Koga H, Ishii N, Dainichi T, et al. An attempt to develop mouse model for anti-laminin\u00a0\u03b31 pemphigoid. J Dermatol Sci. 2013;70(2):108\u201315. https:\/\/doi.org\/10.1016\/j.jdermsci.2013.01.001.","journal-title":"J Dermatol Sci"},{"issue":"4","key":"1444_CR16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaad.2023.11.014","volume":"90","author":"S Goletz","year":"2024","unstructured":"Goletz S, Pigors M, Lari TR, et al. Laminin \u03b24 is a constituent of the cutaneous basement membrane zone and additional autoantigen of anti-p200 pemphigoid. J Am Acad Dermatol. 2024;90(4):790\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2023.11.014.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1444_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/jdv.15444","volume":"33","author":"E Papakonstantinou","year":"2019","unstructured":"Papakonstantinou E, Limberg MM, Gehring M, et al. Neurological disorders are associated with bullous pemphigoid. J Eur Acad Dermatol Venereol. 2019;33(5):925\u20139. https:\/\/doi.org\/10.1111\/jdv.15444.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1444_CR18","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/jdv.13660","volume":"30","author":"YC Lai","year":"2016","unstructured":"Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2016;30(12):2007\u201315. https:\/\/doi.org\/10.1111\/jdv.13660.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1444_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/jid.2010.301","volume":"131","author":"S Bastuji-Garin","year":"2011","unstructured":"Bastuji-Garin S, Joly P, Lemordant P, et al. French study group for bullous diseases. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol. 2011;131(3):637\u201343. https:\/\/doi.org\/10.1038\/jid.2010.301.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1444_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/jid.2010.357","volume":"131","author":"SM Langan","year":"2011","unstructured":"Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol. 2011;131(3):631\u20136. https:\/\/doi.org\/10.1038\/jid.2010.357.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1444_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jaad.2003.12.033","volume":"51","author":"JA Fairley","year":"2004","unstructured":"Fairley JA, Woodley DT, Chen M, Giudice GJ, Lin MS. A patient with both bullous pemphigoid and epidermolysis bullosa acquisita: an example of intermolecular epitope spreading. J Am Acad Dermatol. 2004;51(1):118\u201322. https:\/\/doi.org\/10.1016\/j.jaad.2003.12.033.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1444_CR22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1365-2133.2004.06338.x","volume":"152","author":"E Laffitte","year":"2005","unstructured":"Laffitte E, Burkhard PR, Fontao L, et al. Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis? Br J Dermatol. 2005;152(3):537\u201340. https:\/\/doi.org\/10.1111\/j.1365-2133.2004.06338.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1444_CR23","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/j.1365-2133.2009.09122.x","volume":"160","author":"L Li","year":"2009","unstructured":"Li L, Chen J, Wang B, Yao Y, Zuo Y. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol. 2009;160(6):1343\u20135. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09122.x.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1444_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5021\/ad.2018.30.1.13","volume":"30","author":"HW Jeon","year":"2018","unstructured":"Jeon HW, Yun SJ, Lee SC, Won YH, Lee JB. Mortality and comorbidity profiles of patients with bullous pemphigoid in Korea. Ann Dermatol. 2018;30(1):13\u20139. https:\/\/doi.org\/10.5021\/ad.2018.30.1.13.","journal-title":"Ann Dermatol"},{"key":"1444_CR25","doi-asserted-by":"publisher","first-page":"204062232211307","DOI":"10.1177\/20406223221130707","volume":"13","author":"B Zhang","year":"2022","unstructured":"Zhang B, Chen X, Liu Y, Chen F, Yang N, Li L. Relationship between bullous pemphigoid and metabolic syndrome: a 12-year case-control study conducted in China. Ther Adv Chron Dis. 2022;13:20406223221130708. https:\/\/doi.org\/10.1177\/20406223221130707.","journal-title":"Ther Adv Chron Dis"},{"issue":"2","key":"1444_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamadermatol.2021.5125","volume":"158","author":"WC Shen","year":"2022","unstructured":"Shen WC, Chiang HY, Chen PS, Lin YT, Kuo CC, Wu PY. Risk of all-cause mortality, cardiovascular disease mortality, and cancer mortality in patients with bullous pemphigoid. JAMA Dermatol. 2022;158(2):167\u201375. https:\/\/doi.org\/10.1001\/jamadermatol.2021.5125.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1444_CR27","first-page":"505","volume":"16","author":"DE Sholter","year":"2000","unstructured":"Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol. 2000;16(4):505\u201311.","journal-title":"Can J Cardiol"},{"issue":"5","key":"1444_CR28","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1365-2133.2012.11108.x","volume":"167","author":"R della Torre","year":"2012","unstructured":"della Torre R, Combescure C, Cort\u00e9s B, et al. Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. Br J Dermatol. 2012;167(5):1111\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11108.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1444_CR29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jaad.2019.04.029","volume":"81","author":"A Lamberts","year":"2019","unstructured":"Lamberts A, Meijer JM, Pas HH, Diercks GFH, Horv\u00e1th B, Jonkman MF. Nonbullous pemphigoid: insights in clinical and diagnostic findings, treatment responses, and prognosis. J Am Acad Dermatol. 2019;81(2):355\u201363. https:\/\/doi.org\/10.1016\/j.jaad.2019.04.029.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1444_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clindermatol.2011.03.013","volume":"30","author":"M Meurer","year":"2012","unstructured":"Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol. 2012;30(1):78\u201383. https:\/\/doi.org\/10.1016\/j.clindermatol.2011.03.013.","journal-title":"Clin Dermatol"},{"issue":"6","key":"1444_CR31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8805","volume":"12","author":"S Alkeraye","year":"2020","unstructured":"Alkeraye S, AlZamil LR, Alenazi S. Dapsone in the management of pemphigus and pemphigoid: rediscovery of its long-lost efficacy. Cureus. 2020;12(6):e8805. https:\/\/doi.org\/10.7759\/cureus.8805.","journal-title":"Cureus"},{"issue":"8","key":"1444_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002292.pub4","volume":"8","author":"S Singh","year":"2023","unstructured":"Singh S, Kirtschig G, Anchan VN, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2023;8(8):CD002292. https:\/\/doi.org\/10.1002\/14651858.CD002292.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1444_CR33","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3390\/jcm12041638","volume":"12","author":"M Wojtczak","year":"2023","unstructured":"Wojtczak M, Nolbrzak A, Wo\u017aniacka A, \u017bebrowska A. Can methotrexate be employed as monotherapy for bullous pemphigoid? analysis of efficiency and tolerance of methotrexate treatment in patients with bullous pemphigoid. J Clin Med. 2023;12(4):1638. https:\/\/doi.org\/10.3390\/jcm12041638.","journal-title":"J Clin Med"},{"issue":"1","key":"1444_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jaad.2019.03.049","volume":"81","author":"M Polansky","year":"2019","unstructured":"Polansky M, Eisenstadt R, DeGrazia T, Zhao X, Liu Y, Feldman R. Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients. J Am Acad Dermatol. 2019;81(1):179\u201386. https:\/\/doi.org\/10.1016\/j.jaad.2019.03.049.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1444_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ad.2021.10.018","volume":"114","author":"C Su\u00e1rez-Caranto\u00f1a","year":"2023","unstructured":"Su\u00e1rez-Caranto\u00f1a C, Jim\u00e9nez-Cauh\u00e9 J, Gonz\u00e1lez-Garc\u00eda A, Fern\u00e1ndez-Guarino M, Asunci\u00f3n BM. Low-dose rituximab for bullous pemphigoid. Protocol and single-center experience. Actas Dermosifiliogr. 2023;114(1):62\u20138. https:\/\/doi.org\/10.1016\/j.ad.2021.10.018 . (English, Spanish).","journal-title":"Actas Dermosifiliogr"},{"issue":"7","key":"1444_CR36","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s12325-024-02810-3","volume":"41","author":"DF Murrell","year":"2024","unstructured":"Murrell DF, Joly P, Werth VP, et al. Study design of a phase\u00a02\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT. Adv Ther. 2024;41(7):2991\u20133002. https:\/\/doi.org\/10.1007\/s12325-024-02810-3. (Erratum in: Adv Ther. 2024 Jul;41(7):3014-3015. 10.1007\/s12325-024-02886-x.","journal-title":"Adv Ther"},{"issue":"12","key":"1444_CR37","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.3390\/jcm11123367","volume":"11","author":"R Russo","year":"2022","unstructured":"Russo R, Capurro N, Cozzani E, Parodi A. Use of dupilumab in bullous pemphigoid: where are we now? J Clin Med. 2022;11(12):3367. https:\/\/doi.org\/10.3390\/jcm11123367.","journal-title":"J Clin Med"},{"issue":"9","key":"1444_CR38","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","volume":"159","author":"L Zhao","year":"2023","unstructured":"Zhao L, Wang Q, Liang G, et al. Evaluation of dupilumab in patients with bullous pemphigoid. JAMA Dermatol. 2023;159(9):953\u201360. https:\/\/doi.org\/10.1001\/jamadermatol.2023.2428.","journal-title":"JAMA Dermatol"},{"issue":"32","key":"1444_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jdcr.2022.12.006","volume":"26","author":"D Nash","year":"2022","unstructured":"Nash D, Kirchhof MG. Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib. JAAD Case Rep. 2022;26(32):81\u20133. https:\/\/doi.org\/10.1016\/j.jdcr.2022.12.006.","journal-title":"JAAD Case Rep"},{"issue":"15","key":"1444_CR40","doi-asserted-by":"publisher","first-page":"1464474","DOI":"10.3389\/fimmu.2024.1464474","volume":"21","author":"X Li","year":"2024","unstructured":"Li X, Zhang L, Gu H, He W, Zhai Z, Zhang M. Treatment and molecular analysis of bullous pemphigoid with tofacitinib: a case report and review of current literature. Front Immunol. 2024;21(15):1464474. https:\/\/doi.org\/10.3389\/fimmu.2024.1464474.","journal-title":"Front Immunol"},{"key":"1444_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110591","volume":"122","author":"H Li","year":"2023","unstructured":"Li H, Wang H, Qiao G, Liu Y, Zhang F, Pan F. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: a case report and review of the literature. Int Immunopharmacol. 2023;122: 110591. https:\/\/doi.org\/10.1016\/j.intimp.2023.110591.","journal-title":"Int Immunopharmacol"},{"issue":"14","key":"1444_CR42","doi-asserted-by":"publisher","first-page":"1220887","DOI":"10.3389\/fimmu.2023.1220887","volume":"10","author":"D Huang","year":"2023","unstructured":"Huang D, Zhang Y, Kong L, Lu J, Shi Y. Janus kinase inhibitors in autoimmune bullous diseases. Front Immunol. 2023;10(14):1220887. https:\/\/doi.org\/10.3389\/fimmu.2023.1220887.","journal-title":"Front Immunol"},{"issue":"13","key":"1444_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928621","volume":"13","author":"P Cao","year":"2022","unstructured":"Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol. 2022;13(13): 928621. https:\/\/doi.org\/10.3389\/fimmu.2022.928621.","journal-title":"Front Immunol"},{"key":"1444_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40257-016-0235-z","volume":"18","author":"S Kartan","year":"2017","unstructured":"Kartan S, Shi VY, Clark AK, et al. Paraneoplastic pemphigus and autoimmune blistering diseases associated with neoplasm: characteristics, diagnosis, associated neoplasms, proposed pathogenesis. Treatment Am J Clin Dermatol. 2017;18:105\u201326. https:\/\/doi.org\/10.1007\/s40257-016-0235-z.","journal-title":"Treatment Am J Clin Dermatol"},{"issue":"2","key":"1444_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.5826\/dpc.0902a07","volume":"9","author":"M La Placa","year":"2019","unstructured":"La Placa M, Balestri R, Tartari F, et al. Mucous membrane pemphigoid-associated malignancies: case series and a brief overview of the literature. Dermatol Pract Concept. 2019;9(2):119\u201325. https:\/\/doi.org\/10.5826\/dpc.0902a07.","journal-title":"Dermatol Pract Concept"},{"key":"1444_CR46","volume-title":"Ophthalmic pearls","author":"A Geevarghese","year":"2022","unstructured":"Geevarghese A, Kim E. Mucous membrane pemphigoid with ocular involvement: a primer. In: Jeng BH, editor. Ophthalmic pearls. American Academy of Ophthalmology; 2022."},{"issue":"8","key":"1444_CR47","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.jid.2023.02.012","volume":"143","author":"JA Fairley","year":"2023","unstructured":"Fairley JA, Crowe TP, Fakhimi M, et al. Disease endotypes predict the severity of mucous membrane pemphigoid. J Invest Dermatol. 2023;143(8):1479-1486.e3. https:\/\/doi.org\/10.1016\/j.jid.2023.02.012.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"1444_CR48","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/jamadermatol.2021.1036","volume":"157","author":"H Rashid","year":"2021","unstructured":"Rashid H, Meijer JM, Diercks GFH, et al. Assessment of diagnostic strategy for mucous membrane pemphigoid. JAMA Dermatol. 2021;157(7):780\u20137. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1036.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"1444_CR49","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jop.13054","volume":"49","author":"R Walton","year":"2020","unstructured":"Walton R, Robinson M, Carrozzo M. A service evaluation of the diagnostic testing for mucous membrane pemphigoid in a UK oral medicine unit. J Oral Pathol Med. 2020;49(7):687\u201392. https:\/\/doi.org\/10.1111\/jop.13054.","journal-title":"J Oral Pathol Med"},{"key":"1444_CR50","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41415-024-7074-8","volume":"236","author":"G Davis","year":"2024","unstructured":"Davis G, Hathway R, Shipley D, et al. The management of pemphigus vulgaris and mucous membrane pemphigoid in a joint oral medicine and dermatology clinic: a five-year narrative review. Br Dent J. 2024;236:311\u20136. https:\/\/doi.org\/10.1038\/s41415-024-7074-8.","journal-title":"Br Dent J"},{"issue":"3","key":"1444_CR51","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jaad.2021.12.021","volume":"87","author":"ML Hrin","year":"2022","unstructured":"Hrin ML, Jorizzo JL, Feldman SR, Shah RE, Huang WW. Dermatologic management of ocular mucous membrane (cicatricial) pemphigoid with mycophenolate mofetil in 38 patients. J Am Acad Dermatol. 2022;87(3):653\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2021.12.021.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1444_CR52","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaad.2020.12.056","volume":"87","author":"Y Lytvyn","year":"2022","unstructured":"Lytvyn Y, Rahat S, Mufti A, et al. Biologic treatment outcomes in mucous membrane pemphigoid: a systematic review. J Am Acad Dermatol. 2022;87(1):110\u201320. https:\/\/doi.org\/10.1016\/j.jaad.2020.12.056.","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"1444_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915205","volume":"30","author":"G Bohelay","year":"2022","unstructured":"Bohelay G, Alexandre M, Le Roux-Villet C, et al. Rituximab therapy for mucous membrane pemphigoid: a retrospective monocentric study with long-term follow-up in 109 patients. Front Immunol. 2022;30(13):915205. https:\/\/doi.org\/10.3389\/fimmu.2022.915205.","journal-title":"Front Immunol"},{"issue":"7","key":"1444_CR54","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/exd.14829","volume":"32","author":"N Kianfar","year":"2023","unstructured":"Kianfar N, Dasdar S, Daneshpazhooh M, Aryanian Z, Goodarzi A. A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: special focus on indication and combination therapy. Exp Dermatol. 2023;32(7):934\u201344. https:\/\/doi.org\/10.1111\/exd.14829.","journal-title":"Exp Dermatol"},{"issue":"27","key":"1444_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jdcr.2022.07.013","volume":"16","author":"KM Burningham","year":"2022","unstructured":"Burningham KM, Cao J, Dominguez AR. Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate. JAAD Case Rep. 2022;16(27):67\u20139. https:\/\/doi.org\/10.1016\/j.jdcr.2022.07.013.","journal-title":"JAAD Case Rep"},{"issue":"22","key":"1444_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101104","volume":"21","author":"H James","year":"2021","unstructured":"James H, Paley GL, Brasington R, Custer PL, Margolis TP, Paley MA. Tofacitinib for refractory ocular mucous membrane pemphigoid. Am J Ophthalmol Case Rep. 2021;21(22):101104. https:\/\/doi.org\/10.1016\/j.ajoc.2021.101104.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"4","key":"1444_CR57","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00105-019-4377-9","volume":"70","author":"HA Juratli","year":"2019","unstructured":"Juratli HA, S\u00e1rdy M. Lineare IgA-dermatose [Linear IgA bullous dermatosis]. Hautarzt. 2019;70(4):254\u20139. https:\/\/doi.org\/10.1007\/s00105-019-4377-9.","journal-title":"Hautarzt"},{"issue":"6","key":"1444_CR58","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2340\/00015555-3154","volume":"99","author":"J Lammer","year":"2019","unstructured":"Lammer J, Hein R, Roenneberg S, Biedermann T, Volz T. Drug-induced linear IgA bullous dermatosis: a case report and review of the literature. Acta Derm Venereol. 2019;99(6):508\u201315. https:\/\/doi.org\/10.2340\/00015555-3154.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1444_CR59","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S0733-8635(18)30247-X","volume":"11","author":"EP Smith","year":"1993","unstructured":"Smith EP, Zone JJ. Dermatitis herpetiformis and linear IgA bullous dermatosis. Dermatol Clin. 1993;11(3):511\u201326.","journal-title":"Dermatol Clin"},{"key":"1444_CR60","doi-asserted-by":"publisher","DOI":"10.1201\/b14278","volume-title":"Mayo clinic atlas of immunofluorescence in dermatology: patterns and target antigens","author":"AN Kalaaji","year":"2006","unstructured":"Kalaaji AN, Nicolas MEO. Mayo clinic atlas of immunofluorescence in dermatology: patterns and target antigens. 1st ed. Boca Raton: CRC; 2006. https:\/\/doi.org\/10.1201\/b14278.","edition":"1"},{"issue":"3","key":"1444_CR61","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36481","volume":"15","author":"M Khan","year":"2023","unstructured":"Khan M, Park L, Skopit S. Management options for linear immunoglobulin\u00a0A (IgA) bullous dermatosis: a literature review. Cureus. 2023;15(3):e36481. https:\/\/doi.org\/10.7759\/cureus.36481.","journal-title":"Cureus"},{"issue":"2","key":"1444_CR62","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.iac.2012.04.004","volume":"32","author":"VA Venning","year":"2012","unstructured":"Venning VA. Linear IgA disease: clinical presentation, diagnosis, and pathogenesis. Immunol Allergy Clin North Am. 2012;32(2):245\u201353, vi. https:\/\/doi.org\/10.1016\/j.iac.2012.04.004.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"1444_CR63","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1517\/14728222.2014.877891","volume":"18","author":"X Li","year":"2014","unstructured":"Li X, Kimberly RP. Targeting the Fc receptor in autoimmune disease. Expert Opin Ther Targets. 2014;18(3):335\u201350. https:\/\/doi.org\/10.1517\/14728222.2014.877891.","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"1444_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2024.100339","volume":"5","author":"M Karakioulaki","year":"2024","unstructured":"Karakioulaki M, Dunn P, Murrell DF, et al. Advances in pemphigus and pemphigoid: a report of the international meeting of the pemphigus and pemphigoid foundation in Thessaloniki, Greece. JID Innov. 2024;5(2):100339. https:\/\/doi.org\/10.1016\/j.xjidi.2024.100339.","journal-title":"JID Innov"},{"issue":"2","key":"1444_CR65","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/jcm10020364","volume":"10","author":"E Antonelli","year":"2021","unstructured":"Antonelli E, Bassotti G, Tramontana M, et al. Dermatological manifestations in inflammatory bowel diseases. J Clin Med. 2021;10(2):364. https:\/\/doi.org\/10.3390\/jcm10020364.","journal-title":"J Clin Med"},{"issue":"15","key":"1444_CR66","doi-asserted-by":"publisher","first-page":"175628482211153","DOI":"10.1177\/17562848221115312","volume":"28","author":"C Bezzio","year":"2022","unstructured":"Bezzio C, Della Corte C, Vernero M, Di Luna I, Manes G, Saibeni S. Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations. Therap Adv Gastroenterol. 2022;28(15):17562848221115312. https:\/\/doi.org\/10.1177\/17562848221115312.","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"1444_CR67","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3390\/jcm12031139","volume":"12","author":"D Te\u0161anovi\u0107 Perkovi\u0107","year":"2023","unstructured":"Te\u0161anovi\u0107 Perkovi\u0107 D, Bukvi\u0107 Mokos Z, Marinovi\u0107 B. Epidermolysis bullosa acquisita-current and emerging treatments. J Clin Med. 2023;12(3):1139. https:\/\/doi.org\/10.3390\/jcm12031139.","journal-title":"J Clin Med"},{"issue":"5","key":"1444_CR68","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/trf.16341","volume":"61","author":"SL Wyckoff","year":"2021","unstructured":"Wyckoff SL, Hudson KE. Targeting the neonatal Fc receptor (FcRn) to treat autoimmune diseases and maternal-fetal immune cytopenias. Transfusion. 2021;61(5):1350\u20134. https:\/\/doi.org\/10.1111\/trf.16341.","journal-title":"Transfusion"},{"issue":"Suppl","key":"1444_CR69","doi-asserted-by":"publisher","first-page":"s345","DOI":"10.25251\/skin.8.supp.345","volume":"8","author":"S Vassileva","year":"2024","unstructured":"Vassileva S. Overview of clinical trials with efgartigimod in autoimmune blistering diseases: pemphigus vulgaris and pemphigus foliaceus (ADDRESS and ADDRESS+) and bullous pemphigoid (BALLAD and BALLAD+). SKIN J Cutan Med. 2024;8(Suppl):s345. https:\/\/doi.org\/10.25251\/skin.8.supp.345.","journal-title":"SKIN J Cutan Med"},{"issue":"6","key":"1444_CR70","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/jamadermatol.2022.1156","volume":"158","author":"CD Sadik","year":"2022","unstructured":"Sadik CD, Rashid H, Hammers CM, et al. Evaluation of nomacopan for treatment of bullous pemphigoid: a phase\u00a02a nonrandomized controlled trial. JAMA Dermatol. 2022;158(6):641\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2022.1156.","journal-title":"JAMA Dermatol"},{"key":"1444_CR71","unstructured":"AstraZeneca. A study to investigate the use of benralizumab in patients with bullous pemphigoid (FJORD) [Clinical trial, NCT04612790]. ClinicalTrials.gov. 2024"},{"issue":"2","key":"1444_CR72","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/jdv.20156","volume":"39","author":"MA White","year":"2025","unstructured":"White MA, Hoffman VM, Yale M, Strong R, Tomayko MM. Psychosocial burden of autoimmune blistering diseases: a comprehensive survey study. J Eur Acad Dermatol Venereol. 2025;39(2):350\u20136. https:\/\/doi.org\/10.1111\/jdv.20156.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01444-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01444-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01444-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T09:59:36Z","timestamp":1748685576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01444-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":72,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1444"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01444-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Emma L. Myers and Donna A. Culton have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}